3.58
+0.01(+0.28%)
Currency In USD
| Previous Close | 3.57 |
| Open | 3.68 |
| Day High | 4 |
| Day Low | 3.58 |
| 52-Week High | 15.91 |
| 52-Week Low | 3.1 |
| Volume | 16,919 |
| Average Volume | 717,445 |
| Market Cap | 22.82M |
| PE | -0.96 |
| EPS | -3.72 |
| Moving Average 50 Days | 5.42 |
| Moving Average 200 Days | 6.24 |
| Change | 0.01 |
If you invested $1000 in Exicure, Inc. (XCUR) since IPO date, it would be worth $7.7 as of February 21, 2026 at a share price of $3.58. Whereas If you bought $1000 worth of Exicure, Inc. (XCUR) shares 5 years ago, it would be worth $9.99 as of February 21, 2026 at a share price of $3.58.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant
GlobeNewswire Inc.
Feb 05, 2026 12:00 PM GMT
Phase 2 data demonstrate differentiated CXCR4 inhibition kinetics enabling same-day cell collection, with rapid lymphocyte mobilization supporting potential therapeutic applications beyond transplantREDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWI
Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings
GlobeNewswire Inc.
Jan 21, 2026 12:00 PM GMT
REDWOOD CITY, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that it will present a poster at the upcoming 2026 Tandem
Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting
GlobeNewswire Inc.
Dec 08, 2025 9:30 PM GMT
REDWOOD CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced positive results from its completed Phase 2 trial evaluat